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Background: The timing of highly active antiretroviral therapy (HAART) after a tuberculosis
diagnosis  in HIV-infected patients can affect clinical outcomes and survival. We  compared
survival  after tuberculosis diagnosis in HIV-infected adults who initiated HAART and tuber-
culosis therapy simultaneously to those who delayed the start of HAART for at least two
months.
Methods:  The THRio cohort includes 17,983 patients receiving HIV care in 29 public clinics
in  Rio de Janeiro, Brazil. HAART-naïve patients at the time of a new TB diagnosis between
September  2003 and June 2008 were included. Survival was measured in days from diagnosis
of  TB. We  compared survival among patients who initiated HAART within 60 days of TB
treatment  (simultaneous – ST) to those who started HAART >60 days of TB treatment or
never  started (deferred – DT). Kaplan–Meier plots and Cox proportional hazards regression
analyses  were conducted.
Results:  Of 947 patients diagnosed with TB, 572 (60%) were HAART naïve at the time of TB
diagnosis;  135 were excluded because of missing CD4 count results. Among the remaining437  TB patients, 56 (13%) died during follow-up: 25 (10%) among ST patients and 31 (16%)in  DT group (p = 0.08). ST patients had lower median CD4 counts at TB diagnosis than DT
patients  (106 vs. 278, p < 0.001). Cox proportional hazards utilizing propensity score analy-
sis  showed that DT patients were more likely to die (adjusted HR = 1.89; 95% CI: 1.05–3.40;
p  = 0.03).
∗ Corresponding author at: Rua Cupertino Durão, 219, Bloco B, apto 404, Rio de Janeiro, 22441-030, RJ, Brazil.
E-mail  addresses: valsaraceni@gmail.com, valsaraceni@yahoo.com (V. Saraceni).
ttp://dx.doi.org/10.1016/j.bjid.2014.02.004
413-8670/© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-ND
492  b r a z j i n f e c t d i s . 2 0 1 4;1  8(5):491–495
Conclusion: HAART administered simultaneously with TB therapy was associated with
improved survival after TB diagnosis. HAART should be given to patients with HIV-related
TB as soon as clinically feasible.
© 2014 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Highly active antiretroviral therapy (HAART) signiﬁcantly
improves survival in HIV-infected patients with opportunis-
tic  infections, but the optimal time to initiate HAART in
patients  with HIV-related tuberculosis (TB) poses a challenge
to  clinicians and patients.1,2 Recent World Health Organi-
zation recommendations state that HIV-infected patients
with  active TB should initiate HAART as soon as possible
after  TB treatment, irrespective of CD4 cell count,3 though
the  quality of the evidence supporting these recommenda-
tions is characterized as low or moderate. The SAPiT trial
in  South Africa reported a 56% mortality reduction among
patients starting HAART within four weeks after the start
of  TB therapy or within four weeks of completion of the
intensive phase of TB therapy compared to those initiat-
ing  HAART within four weeks of TB treatment completion.4
Further analysis of the SAPiT trial suggests that the pro-
tection  conferred is equally strong if treatment is started
at  either time during TB treatment.5 The recent STRIDE
trial reported no mortality difference between those start-
ing  HAART within two weeks of TB treatment initiation and
those  starting within 8–12 weeks after TB treatment start,6
though both trials report a signiﬁcant drop in mortality
among early starters with advanced immunosuppression. The
CAMELIA  clinical trial in Cambodia found a reduction of 34%
among  patients starting HAART eight weeks after TB treat-
ment  start compared to those starting HAART within two
weeks  in a population with 72% having a CD4 < 50 cells/mm3.7
Studies in developed countries have shown that patients
with  very advanced HIV disease have better survival if
HAART  is given during TB treatment,8–11 though the risks
of  immune reconstitution inﬂammatory syndrome (IRIS),12,13
drug interactions and additive drug toxicity raise concerns
about  early initiation of HAART in TB/HIV co-infection.14 The
three  clinical trials suggest that HAART be initiated very
early  for those with advanced immunosuppression; however,
those  with higher CD4 counts at the time of TB diagnosis
can  wait to initiate HAART and not compromise survival,
while  also reducing the risk of IRIS and other complica-
tions.
Rio de Janeiro City, Brazil, has a large population of patients
with  TB/HIV co-infection, and TB is an important cause of
death  in individuals with AIDS.15 The TB/HIV in Rio (THRio)
study  was  a cluster randomized trial16 designed to evaluate
the  impact of TB screening and isoniazid preventive therapy
in  HIV-patients receiving care at 29 public health units in Rio
de  Janeiro. In Brazil, HIV-infected patients have free access to
HAART and TB therapy in public health clinics, and treatment
in  the private sector is not available. We  conducted a survival
analysis  after TB diagnosis according to the timing of HAART
initiation  in the THRio cohort.Methods
This is an observational cohort survival analysis after the diag-
nosis  of TB in HIV-infected patients receiving care in THRio
clinics.  We compared survival in patients receiving simul-
taneous  HAART and TB therapy (HAART started within 60
days  of TB diagnosis) with deferred HAART (HAART started
>60  days but <365 days after TB diagnosis, or no HAART).
Patients who started HAART >365 days after their TB diag-
nosis  were censored at that point. Data collection for THRio
has  been described previously.16 In brief, 29 pubic primary
health clinics treating HIV-infected patients were  randomly
assigned to begin implementing TB screening and isoniazid
preventive therapy (IPT) in September 2005. Patient data were
abstracted  from medical records starting at the date of HIV
diagnosis  and included age, gender, HIV diagnosis date, his-
tory  of HAART and date of initiation, history of opportunistic
infections, CD4 counts, tuberculin skin tests, IPT, and viral
loads.  For the current analysis, patients were included if they
(1)  were  HIV-positive by serologic testing; (2) had a ﬁrst diagno-
sis  of active TB between September 1, 2003 and June 30, 2008;
(3)  were not receiving HAART for more  than 60 days at the time
of  TB diagnosis; and (4) were diagnosed with HIV either prior
to  TB diagnosis or within 30 days after TB diagnosis. TB was
deﬁned  according to Brazilian guidelines, and included symp-
toms,  X-rays, sputum smears and cultures. TB treatment was
given  to all patients using the Brazilian regimen of three drugs
daily  for two months followed by two drugs for four months.17
The primary outcome was  all-cause mortality. The primary
exposure of interest was  time elapsed since HAART initiation,
which  was  divided into two categories: HAART initiated within
60  days of TB treatment start date (simultaneous therapy (ST))
and  HAART initiated more  than 60 days after TB start date or
never  started during the study period (deferred therapy (DT)).
Other  covariates that were  assessed included CD4  count at TB
diagnosis,  gender, and age. Patients were censored either at
the  last clinic visit, or on December 31, 2008, or at HAART start
date  if HAART start date was  more  than one year after TB treat-
ment  start date which ever occurred ﬁrst. Death reporting was
abstracted  from patient medical records or from the National
Mortality  System (SIM), after linkage with the THRio cohort,
using  an algorithm described elsewhere.18 Date of TB diagno-
sis  was  the date of initiation of TB treatment recorded in the
clinic  charts. HAART was  deﬁned as the use of two nucleoside
reverse  transcriptase inhibitors plus a non-nucleoside reverse
transcriptase inhibitor or one or two protease inhibitors in
combination. Date of HAART initiation was abstracted from
clinic  charts. Date of death was the date recorded in the death
certiﬁcate,  as entered in the SIM. HAART was initiated at the
physicians’  discretion, guided by the Brazilian Recommenda-
tions to Antiretroviral Therapy for HIV-infected Adults and
Adolescents  in use at the time of the study.19
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Table 1 – Predictors of mortality in HIV/TB co-infected patients.
All patients (n = 437) Mortality p-Value
Died (n = 56) Survived (n = 381)
Median age (years; IQR) 36 (29–43) 36 (29–45) 36 (29–42) 0.599
Gender (% male) 306 (70%) 46 (82%) 260 (68%) 0.041
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all  survival. New WHO  guidelines state that HAART should
be  initiated as soon as possible in all patients with HIV
and  active tuberculosis, regardless of CD4 cell count.3 Our
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Descriptive statistics were  performed using t-tests for
ontinuous variables and Fisher’s exact test for categor-
cal  variables. Survival curves were examined using the
aplan–Meier method, and the log rank test was  used to assess
ifferences  in survival functions by group.
Propensity scores were  calculated as follows: a logistic
egression model was  run having DT/ST as the response vari-
ble  and gender, age and CD4 counts as co-variables. Predicted
robabilities from the model were  used to construct quintiles,
hich  were  included in the model as a stratifying variable.
ox  proportional hazards regression analyses were  conducted
nd  propensity scores for HAART initiation by 60 days post-TB
iagnosis  were  used to stratify the baseline hazard function in
rder to minimize bias from treatment by indication.
The THRio study was  approved by the Research Ethics Com-
ittee  of the Municipal Secretary of Health and Civil Defense
f  the Municipality of Rio de Janeiro, Brazil, and the Johns Hop-
ins  Medicine Institutional Review Board. The study received a
aiver of informed consent, as no direct contact with patients
as  undertaken by study staff and all data were deidentiﬁed
rior  to analysis.
esults
here were  17,983 subjects in the THRio cohort for this anal-
sis.  Between September 2003 and June 2008, 947 cases of TB
ere  diagnosed, of whom 572 had no history of exposure to
AART  for greater than 60 days at TB diagnosis. One hundred
hirty-ﬁve patients were excluded from the analysis because
hey  did not have a CD4 count result available within four
onths  of their TB diagnosis. Of the 437 TB/HIV patients in
he  current analysis, 78% of the cases were  male, the median
ge  was  36 years (IQ range: 29–43 years) and the median CD4
ell  count at TB diagnosis was  150 cells/mm3 (IQ range: 67–294
ells).  Of the 389 (89%) who  started HAART at or after TB treat-
ent  start date, 243 started within 60 days of TB treatment
tart  date (ST), 125 started HAART >60 days and ≤365 days after
B  treatment start date (DT), and 21 started HAART >365 days
fter  TB treatment start date and were censored at HAART
tart  date (DT). Forty-eight patients never started HAART in
he study period (DT) and were censored as described. ST
atients  did not differ from DT patients in age, gender or RNA
iral  load at the time of TB diagnosis (Table 2). ST patients had
ower  median CD4 cell counts at the time of TB diagnosis (106
s.  278 cell/mm3, p < 0.001). Fifty-six patients (13%) died dur-
ng  a median of 2.1 years of follow-up (2212 person-years),
t a mortality rate of 7.6 deaths per 100 person-years. The
edian  time to death was  338 days. Subjects who died had
imilar  baseline CD4 counts and HIV viral loads at time of TB
iagnosis  as those who survived (Table 1).157 (72–243) 150 (63–300) 0.754
31 (55%) 163 (43%) 0.004
Among 243 TB patients in the ST group, 25 (10%) died dur-
ing  follow-up compared to 31 of 194 (16%) in the DT group
(p  = 0.085). Kaplan–Meier estimates of survival after TB diag-
nosis  stratiﬁed by timing of HAART initiation are shown in
Fig.  1. ST patients were signiﬁcantly less likely to die over the
follow-up  period than DT patients (log-rank test p = 0.02). Uni-
variate  Cox analysis revealed that delaying therapy increased
mortality  risk 45% (HR = 1.45; 95% CI: 1.05–2.00). Adjusted Cox
proportional  hazards modeling revealed an 89% increased
risk  in mortality among DT patients compared to ST patients
(RH  = 1.89; 95% CI: 1.05–3.40; p = 0.03), taking the propensity
score into account (Table 3). No other covariates were  asso-
ciated  with increased mortality.
Discussion
In this cohort of 437 patients with HIV-related TB who  were
HAART  naïve at the time of TB diagnosis, not receiving
HAART within 60 days after TB diagnosis was  associ-
ated with an 89% increased risk of mortality. Patients
who received HAART early had signiﬁcantly lower CD4 cell
counts  at the time of TB diagnosis but had better over-Fig. 1 – Time from TB diagnosis to death of HAART-naïve
HIV/TB co-infected patients with HAART deferred at least
60  days following initiation of TB therapy (DT) and patients
starting  HAART at the time of TB therapy initiation.
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Table 2 – Patient characteristics by timing of HAART for TB/HIV co-infection.
Timing of HAART for HIV/TB co-infected patients p-Value
ST (n = 243) DT (n = 194)
Median age (years) 35.8 36.0 0.835
Gender  (% male) 70.8 69.1 0.753
Median CD4 at TB diagnosis 106 278 <0.001
Median HIV VL at TB diagnosis 5.1 5.0 0.574
Mortality at the end of follow-up (#, %) 25 (10.3) 31 (16.0) 0.085
Table 3 – Cox regression model, univariate and multivariate analysis.
Covariates HR (95% CI) p-Value Adjusted HRa (95% CI) p-Value
Female 0.94 (0.68–1.30) 0.71 0.46 (0.21–1.01) 0.05
Age (years) 0.99 (0.98–1.01) 0.43 1.00 (0.97–1.04) 0.66
CD4 per 100 change HR (absolute) 1.00 (0.99–1.00) 0.52 0.90 (0.66–1.22) 0.48
Deferred HAART 1.45 (1.05–2.00) 0.02 1.89 (1.05–3.40) 0.03
r
2. Nachega JB, Rosenkranz B, Simon G, Chaisson RE, Diacon A,
Taljaard  J. Management of adult active tuberculosis disease in
era  of HIV pandemic, current practices and futurea Stratiﬁed by propensity score quintile.
data strongly support the use of HAART in all patients
with HIV-related TB as early after TB treatment as possi-
ble  in Brazil, with a reduction in mortality that was  even
greater  than what has been reported in recent clinical
trials.4–7
HAART has been shown to decrease the incidence of TB
in  Africa,20,21 Brazil,22,23 and other developed and developing
countries,24–26 and HAART strongly reduces mortality among
patients co-infected with HIV and TB10,11 as seen in our
study. The protection offered by HAART has been consistently
seen  across CD4 cell strata, but most markedly in patients
with  most advanced immunodeﬁciency.26,4–7 In our study, CD4
at  the time of TB diagnosis did not independently impact
survival among co-infected patients, though CD4 was  signiﬁ-
cantly  lower in patients starting HAART early. Most likely, the
increase  in the CD4 cell count explains most of the protec-
tion  afforded by HAART, although other factors, such as HIV
viral  load and levels of other T cell subpopulations, may  play
a  role.26 Patients who fail to increase their CD4 counts after
HAART  initiation are at higher risk of recurrent TB.27
Survival between the ST and DT groups did not begin to
diverge  until about 1.5 years following TB diagnosis, well after
TB  treatment had been completed. The SAPiT Trial in South
Africa  and the CAMELIA Trial also did not see a signiﬁcant
survival beneﬁt until after six months of TB therapy.4,7
This clinical cohort study has some limitations. Our data
were  collected from patient medical records, and information
on  drug toxicity and IRIS was  generally not available. Drug-
related  toxicity and IRIS events occur more  commonly at lower
CD4  counts and may  affect morbidity, though clinical trials
show  no impact of IRIS on mortality. In addition, the THRio
study  is based on data abstracted from medical charts, and
exposure  to HAART was  allocated at physicians’ discretion,
based  on the Brazilian Recommendations for Antiretroviral
Therapy for Adults and Adolescents,19 which guides HIV care
in  Brazil. These guidelines have recently been updated stating
that  for patients with pulmonary TB with a cavitary lesion, a
CD4 cell count should be conducted 30 days after starting TB
treatment28 and that HAART should be started if CD4 count is
less  than 350 cells/mm3.Conclusion
We showed that HAART initiated early after TB treatment in
co-infected  patients was  associated with an 89% reduction
in  the risk of death compared to delayed HAART initia-
tion.  Thus, we  provide further evidence of the importance of
early  HAART in increasing survival among HIV/TB co-infected
patients. Strategies to promote the early diagnosis of HIV
infection  among TB patients and early initiation of HAART
play  important roles in improving the quality of care for
patients  co-infected with TB and HIV.
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